Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 2 - NSCLC, metastatic

3200 - CTONG 1509 : Phase 3 study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC


30 Sep 2019


Proffered Paper 2 - NSCLC, metastatic


Tumour Site

Non-Small Cell Lung Cancer


Qing Zhou


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


Q. Zhou1, Y. Wu2, Y. Cheng3, Y. Liu4, G. Chen5, J. Cui6, N. Yang7, Y. Song8, X. Li9, S. Lu10, J. Zhou11, Z. Ma12, S. Yu13, C. Huang14, Y. Shu15

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, 510055 - Guangzhou/CN
  • 2 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou/CN
  • 3 Department Of Thoracic Oncology, Jilin Cancer Hospital, Changchun/CN
  • 4 Department Of Medical Oncology, The First Hospital of China Medical University, Shenyang/CN
  • 5 Medical Oncology, Affiliated Cancer Hospital of Harbin Medical University, 150081 - Harbin/CN
  • 6 Cancer Center, The First Hospital of Jilin University, 130021 - Changchun/CN
  • 7 Department Of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha/CN
  • 8 Respiratory Medicine, Jinling Hospital, 210002 - Nanjing/CN
  • 9 Medical Oncology, Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute, Shenyang/CN
  • 10 Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai/CN
  • 11 Respiratory Medicine, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou/CN
  • 12 Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou/CN
  • 13 Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN
  • 14 Medical Oncology, Fujian Cancer Hospital, The Affiliated Cancer Hospital of Fujian Medical University, Fuzhou/CN
  • 15 Medical Oncology, Jiangsu Province Hospital,The First Affiliated Hospital with Nanjing Medical University, Nanjing/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3200


This study is an open-labeled, randomized, multicenter phase III study to investigate the efficacy and safety of bevacizumab (B) with or without erlotinib (E) in Chinese EGFR-mutated non-small cell lung cancer (NSCLC) patients (NCT02759614).


Patients with advanced non-squamous NSCLC harbouring EGFR-mutation were randomly (1:1) assigned to receive either combination with erlotinib (150 mg daily) plus bevacizumab (15 mg/kg iv q3w) or erlotinib (150 mg daily). Random assignment was stratified by sex (female/male), disease stage (stage IIIb vs. stage IV vs. recurrence), and EGFR gene mutation (exon 19 deletion vs. exon 21 L858R). The primary endpoint was Progression-free survival (PFS), as determined by an independent review committee (IRC). Secondary endpoints were PFS by investigator, tumor response (by IRC and investigator), overall survival (OS), time to failure (TTF), safety, patient-reported outcome (PRO) and exploratory biomarker analysis. Next-generation sequencing (NGS) of a 448-gene panel and transcriptome sequencing (RNA-Seq) was used for resistance biomarker analysis of paired frozen tissue samples.


From Mar 31, 2016 to Jul 26, 2017, 311 patients from 14 centers across China were randomized to receive BE (N = 157) or E (N = 154). Median follow-up time was 22 months for BE and 21.5 months for E. Baseline characteristics were well balanced in each arm. The median PFS by IRC was 18.0 months (95% CI 15.2-20.7) in BE and 11.3 months (95%CI 9.8-13.8) in E (p < 0.001) (HR = 0.55,95%CI 0.41-0.75). The median PFS per investigator was 18.0 months (95% CI 15.2-20.7) in BE and 11.2 months (95%CI 9.7-12.5) in E (p < 0.001) (HR = 0.57,95% CI 0.44-0.75). The objective response rate by IRC in the BE and E groups was 86.3% and 84.7%, respectively (p = 0.741). The most common grade 3 or worse adverse events in BE group were hypertension, proteinuria and rash; and in the E alone group were rash, elevated alanine aminotransferase and elevated aspartate aminotransferase. Results for resistance biomarker analysis will be presented onsite.


As compared with E alone, B plus E showed superior efficacy with acceptable tolerability. This regimen could be a new standard first-line regimen in EGFR mutated NSCLC.

Clinical trial identification


Editorial acknowledgement

Li Zhang, from Shanghai Roche Pharmaceuticals Ltd.

Legal entity responsible for the study

Guangdong Association of Clinical Trials (GACT).


Shanghai Roche Pharmaceuticals Ltd.


Q. Zhou: Honoraria (self): AstraZeneca; Honoraria (self): Roche. Y. Wu: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self): Pierre Fabre; Honoraria (self): Pfizer; Honoraria (self): Sanofi; Advisory / Consultancy: Merck; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.